Newtyn Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Newtyn Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,000,000	Closed	-$4.62M	–	55
2020 Q2	$4.62M	Buy	+1,000,000	New	+$4.49M	1.69%	24

Other funds holding CPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Newtyn Management's CPRX Position: Q3 2020 in Review

Newtyn Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2020, closing a stake of 1,000,000 shares — an estimated $4.62M sold.

Newtyn Management first reported a position in CPRX in Q2 2020 and held it in 1 quarter. The position peaked at $4.62M in Q2 2020. 142 funds tracked by Wall St. Rank hold CPRX as of Q3 2020.

Newtyn Management reported no remaining Catalyst Pharmaceutical position as of Q3 2020 after selling out during the quarter.
Newtyn Management sold 1,000,000 Catalyst Pharmaceutical shares in Q3 2020, an estimated $4.62M.
Newtyn Management first reported a position in Catalyst Pharmaceutical in Q2 2020 and held it in 1 quarter.
Newtyn Management's Catalyst Pharmaceutical position peaked at $4.62M in Q2 2020.
142 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2020.

Based on Newtyn Management's 13F filing for Q3 2020, filed 16 Nov 2020.